CURE: Prior Stroke or TIA OutcomeC + ASAASAHRP value MI/stroke/ CV death 49/274 (17.9%)52/232 (22.4)0.74 (0.50, 1.10)0.13 Non-CABG TIMI major bleeding.

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Prasugrel vs ticagrelor in acute coronary syndromes

Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

on behalf of the TOTAL Investigators

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

NSTE Acute Coronary Syndromes

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:

Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.

(p for noninferiority = 0.01)

Antiplatelet therapy for STEMI: The Case for Clopidogrel

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

LEADER trial: Primary Outcome

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

(p < for group 1 or 2 vs. group 3)

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Table. Clinical Efficacy and Safety

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Rounded incidence values (%) of renal and nonrenal events

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Relative Risk of Events by CHA2DS2-VASc Score

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Ezetimibe/simvastatin

Updates in Anticoagulation: Key Sessions at ESC 2017

(p for noninferiority < 0.001)

What oral antiplatelet therapy would you choose?

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Cystatin C levels and risk of death from all causes

Elevated Admission Plasma Glucose Following ACS

Factor Xa Inhibitors in Coronary Artery Disease

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Baseline Characteristics of the Study Participants

Primary safety endpoint

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

(p for noninferiority = 0.01)

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Section C: Clinical trial update: Oral antiplatelet therapy

Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death

Presentation transcript:

CURE: Prior Stroke or TIA OutcomeC + ASAASAHRP value MI/stroke/ CV death 49/274 (17.9%)52/232 (22.4)0.74 (0.50, 1.10)0.13 Non-CABG TIMI major bleeding 2/274 (0.7%)2/232 (0.9%)0.83 (0.12, 5.88)0.85 Net clinical benefit outcome 49/274 (17.9%)60/232 (25.9%)0.64 (0.44, 0.93)0.02 (N=506) No significant interaction for any outcome Courtesy of Dr. John Eikelboom C=clopidogrel CURE trial (unpublished data)

CURE: Prior Stroke, Age ≥75, Weight <60 kg OutcomeC + ASAASAHR (95% CI)P value MI/stroke/ CV death 279/1763 (15.8%)303/1732 (17.5%)0.89 (0.75, 1.04)0.15 Non-CABG TIMI major bleeding 19/1763 (1.1%)15/1732 (0.9%)1.23 (0.63, 2.42)0.55 Net clinical benefit outcome 298/1763 (16.9%)334/1732 (19.3%)0.86 (0.73, 1.00)0.05 (N=3495) No significant interaction for any outcome CURE trial (unpublished data) Courtesy of Dr. John Eikelboom

CURE and TRITON-TIMI 38: Prior Stroke or TIA Outcome Relative riskAbsolute risk CURETRITONCURETRITON MI/stroke/CV death↓26%↑37%↓45/1000↑47/1000 Non-CABG TIMI major bleeding ↓17%↑146%↓2/1000↑21/1000 Net clinical benefit outcome ↓36%*↑54%*↓80/1000*↑70/1000* *P<0.05 Courtesy of Dr. John Eikelboom; Wiviott et al. N Engl J Med 2007;357(20): CURE trial (unpublished data)